Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
暂无分享,去创建一个
Joan Figueras | Jaume Torras | Gabriel Capellà | Víctor Moreno | V. Moreno | G. Capellá | J. Figueras | E. Jaurrieta | A. Villanueva | D. Molleví | T. Serrano | M. Navarro | J. Torras | Alberto Villanueva | Eduardo Jaurrieta | Matilde Navarro | Teresa Serrano | M. Ginesta | Josep R Germà | David G Molleví | Mireia M Ginestà | Joan Valls | Emilio Ramos | E. Ramos | J. Germà | J. Valls
[1] N. Magné,et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Figueras,et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases , 2001, The British journal of surgery.
[3] W. Enker,et al. Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Ferlay,et al. Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.
[5] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[6] A. Fassina,et al. Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. , 1998, European journal of cancer.
[7] M. Makuuchi,et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. , 1990, Surgery.
[8] J. BotellaLlusiá,et al. [Long-term results]. , 1983, Anales de la Real Academia Nacional de Medicina.
[9] J. Figueras,et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. , 2001, Radiology.
[10] U. Stenram,et al. Resection of Colorectal Liver Metastases: 25-Year Experience , 1998, World Journal of Surgery.
[11] G. Capellá,et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Kawasaki,et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. , 2000, Annals of surgery.
[13] R. Fisher,et al. Genetic Markers of Survival and Liver Recurrence after Resection of Liver Metastases from Colorectal Cancer , 2001, World Journal of Surgery.
[14] B. Dörken,et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Nordlinger,et al. Long‐term survival following resection of colorectal hepatic metastases , 1997, The British journal of surgery.
[16] J. Yokota,et al. Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] D. Smith,et al. p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.
[18] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[19] Richard Stang,et al. Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.
[20] D. Kerr,et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Saw,et al. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer , 2002, The British journal of surgery.
[22] G. Parmigiani,et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Kuroki,et al. High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas , 2002, Oncogene.
[24] M. Leppert,et al. Prognostic significance of p53 mutations in colon cancer at the population level , 2002, International journal of cancer.
[25] B. Iacopetta. TP53 mutation in colorectal cancer , 2003, Human mutation.
[26] S Bengmark,et al. The natural history of primary and secondary malignant tumors of the liver . II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. , 1969, Digestion.
[27] A. Magliocco,et al. Molecular mechanisms of hepatic metastasis in colorectal cancer , 2005, Journal of surgical oncology.
[28] Michael A. Choti,et al. A Phosphatase Associated with Metastasis of Colorectal Cancer , 2001, Science.
[29] D. Chung,et al. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. , 2000, Gastroenterology.
[30] G. Thomas,et al. Association of p53 mutations with short survival in colorectal cancer. , 1994, Gastroenterology.
[31] A. Gouw,et al. P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression , 2005, Clinical Cancer Research.
[32] S Bengmark,et al. The natural history of primary and secondary malignant tumors of the liver I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy , 1969, Cancer.
[33] G. Capellá,et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Kerr,et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. Kelly,et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] R. Lothe,et al. Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G‐banding analysis , 2003, Genes, chromosomes & cancer.
[37] Prognostic significance of proliferative activity, DNA‐ploidy, p53 and Ki‐ras point mutations in colorectal liver metastases , 1998 .
[38] M. Makuuchi,et al. History of intraoperative ultrasound. , 1998, Ultrasound in medicine & biology.
[39] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] K. Lundholm,et al. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection , 2001, Cancer.
[41] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[42] A. Russo,et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.